22 / 23
Chemotherapy and Targeted agents
•
No driver mutations known in Merkel Carcinoma
•
All agents tested in clinical trials revealed low efficcacy
Checkpoint inhibitors
•
High efficcacy demonstrated for anti-PD-L1 (Avelumab) and anti-PD-1
(Pembrolizumab, Nivolumab)) antibodies
•
Approval for Avelumab by EMA in 9/2017
•
Effect of combinations with other strategies is being investigated
of Merkel Carcinoma